The mission of TRB Chemedica Group is to develop innovative and patented pharmaceutical products and medical devices in niche therapeutic areas: rheumatology, ophthalmology and neurology.

Video on Dry Eyeeye_pic.jpg

In recent years the nosology of Dry Eye has greatly changed. Professor Baudouin, MD, PhD from National Ophthalmologiy Hospital XV-XX, Vision Institute of Paris explains through this didactic video the complexity of the Dry Eye disease. Moving beyond the simple name of Dry Eye syndrome, we now consider the condition to be Dry Eye disease, insisting on the lack of tears, the lacrimal inflammation and hyperevaporation leading to self-sustaining loops of neurogenic and palpebral inflammations.

View the video


OSTENIL® mini is indicated for the treatment of symptoms of osteoarthritis in small synovial joints such as the carpometacarpal joint of the hand, the ankle joint, the temporomandibular joint and the facet joint of the spine.

OSTENIL® mini is a solution containing hyaluronic acid for injection into the joint cavity. The net result is a decrease in pain and improvement in joint mobility which may last at least 6 months.

OSTENIL® mini is specifically designed for relief from osteoarthritis in small synovial joints

pdf OSTENIL® MINI instructions for use  
trb_lock.gif Doctor information

  • English